Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Dermatologic 3Breast 3Gastrointestinal 2CNS 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1

Conditions

Melanoma 3

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
saponin QA-21V1 × Dermatologic × Clear all
NCT00003224 2014-11-20

Vaccine Therapy in Treating Patients With Metastatic Melanoma

University of Virginia

Phase 1 Completed
22 enrolled 14 charts
Dermatologic

Melanoma

NCT00003362 2013-06-25

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Dermatologic

Melanoma

NCT00005052 2009-02-09

Vaccine Therapy in Treating Patients With Primary Stage II Melanoma

National Cancer Institute (NCI)

Phase 3 Unknown
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡